From the Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Invest Radiol. 2018 May;53(5):313-318. doi: 10.1097/RLI.0000000000000444.
The purpose of this study is to determine the frequency and severity of acute allergic-like reactions to gadolinium-based contrast media (GBCM) in children before, during, and after the transition from gadopentetate dimeglumine to gadoterate meglumine as our primary clinical GBCM.
Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act-compliant retrospective investigation. Allergic-like reactions to GBCM in pediatric patients were retrospectively assessed from January 2009 to January 2017, which included a departmental change of GBCM from gadopentetate dimeglumine to gadoterate meglumine. Allergic-like reactions were identified from departmental and hospital databases. The number of doses of GBCM was obtained from billing data. Allergic-like reaction frequencies for each GBCM were calculated and compared using the chi-squared test.
A total of 32,365 administrations of GBCM occurred during the study period (327 for gadofosveset trisodium; 672 for gadoxetate disodium; 12,012 for gadoterate meglumine; and 19,354 for gadopentetate dimeglumine). Allergic-like reactions occurred after 21 (0.06%) administrations. Reaction frequencies were not significantly different among the GBCM (0.3% gadofosveset trisodium; 0% gadoxetate disodium, 0.06% gadoterate meglumine, 0.08% gadopentetate dimeglumine; P > 0.05). Ten (47.6%) reactions were mild, 10 (47.6%) were moderate, and 1 (4.8%) was severe. The overall reaction frequency peaked during the 6-month transition period from gadopentetate dimeglumine to gadoterate meglumine (0.20%), compared with 0.07% pretransition (P = 0.048) and 0.04% posttransition (P = 0.0095).
Allergic-like reactions to GBCM in children are rare. Gadoterate meglumine has a reaction frequency that does not significantly differ from other GBCMs. During the transition from gadopentetate dimeglumine to gadoterate meglumine, an increase in the frequency of reported allergic-like reactions was observed, likely reflective of the Weber effect.
本研究旨在确定在将临床常用的钆对比剂从钆喷酸葡胺转换为钆特酸葡胺后,儿童在使用该对比剂前、中、后出现急性类似过敏反应的频率和严重程度。
本研究获得了机构审查委员会的批准,是一项符合《健康保险携带和责任法案》的回顾性调查。回顾性评估了 2009 年 1 月至 2017 年 1 月期间儿科患者使用钆对比剂后的类似过敏反应,其中包括对比剂从钆喷酸葡胺转换为钆特酸葡胺。从科室和医院数据库中确定了类似过敏反应。从计费数据中获得了钆对比剂的剂量数。使用卡方检验计算并比较了每种钆对比剂的类似过敏反应频率。
在研究期间共进行了 32365 次钆对比剂给药(其中 327 次为钆福赛酸钠,672 次为钆塞酸二钠,12012 次为钆特酸葡胺,19354 次为钆喷酸葡胺)。有 21 次(0.06%)给药后出现了类似过敏反应。不同钆对比剂的反应频率无显著差异(钆福赛酸钠为 0.3%,钆塞酸二钠为 0%,钆特酸葡胺为 0.06%,钆喷酸葡胺为 0.08%;P>0.05)。10 次(47.6%)反应为轻度,10 次(47.6%)为中度,1 次(4.8%)为重度。从钆喷酸葡胺转换为钆特酸葡胺的 6 个月过渡期内,总体反应频率最高(0.20%),与转换前的 0.07%(P=0.048)和转换后的 0.04%(P=0.0095)相比有所升高。
儿童使用钆对比剂后出现类似过敏反应的情况较为罕见。与其他钆对比剂相比,钆特酸葡胺的反应频率无显著差异。在从钆喷酸葡胺转换为钆特酸葡胺期间,观察到报告的类似过敏反应频率增加,可能反映了 Weber 效应。